SCHEMBL5318769

SCHEMBL5318769

O=C(O)Nc1cccc(Oc2ccnc(Cl)c2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MITF O75030 1/20 0.51
ALDH1A1 P00352 1/20 0.51
POLB P06746 1/20 0.51
MAPK1 P28482 1/20 0.51
HTT P42858 1/20 0.51
GRM5 P41594 2/20 0.51
BRAF P15056 1/20 0.50
CDK8 P49336 3/20 0.47
MAPT P10636 2/20 0.47
RAB9A P51151 2/20 0.47
MEN1 O00255 1/20 0.47
NPC1 O15118 1/20 0.47
KMT2A Q03164 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
LMNA P02545 1/20 0.46
HPGD P15428 1/20 0.46
RET P07949 1/20 0.46
SMARCA2 P51531 1/20 0.46
SMARCA4 P51532 1/20 0.46
RAF1 P04049 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5450708 0.82 MAP2K7 (0.56) MITFALDH1A1POLBMAPK1HTT
SCHEMBL5319496 0.81 MITF (0.46) MITFALDH1A1POLBMAPK1HTT
SCHEMBL27096906 0.81 ALDH1A1 (0.51) ALDH1A1POLBMAPTSMARCA2SMARCA4
SCHEMBL6392968 0.80 MITF (0.69) MITFALDH1A1POLBMAPK1HTT
SCHEMBL1136858 0.79 MET (0.55) BRAF
SCHEMBL1400789 0.78 SMARCA2 (0.68) GRM5SMARCA2SMARCA4
SCHEMBL16058723 0.77 GRM5 (0.48) GRM5BRAFRAB9AMEN1NPC1
SCHEMBL190319 0.77 LTA4H (0.48) HTTMAPTRAB9AMEN1NPC1
SCHEMBL23213631 0.76 GRM4 (0.52) MITFALDH1A1POLBMAPK1HTT
SCHEMBL15543233 0.76 MAPK14 (0.50) BRAFRETRAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007076473-A2 SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES KALYPSYS, INC. (US) 2007-07-05 WO disclosed
US-20070155764-A1 NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES KALYPSYS, INC. (US) 2007-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155764-A1 NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES BRAF, ARAF, RAF1 MITF 1307/4885ALDH1A1 3164/4885POLB 1642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.